AL
ALLO icon

Aspiriant LLC’s Allogene Therapeutics ALLO Stock Holding History

Aspiriant LLC’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-6,700
Closed -$253K – 200
2020
Q3 		$253K Buy
+6,700
New +$253K 0.02% 192

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Aspiriant LLC's ALLO Position: Q4 2020 in Review

Aspiriant LLC sold out of Allogene Therapeutics (ALLO) in Q4 2020, closing a stake of 6,700 shares — an estimated $253K sold.

Aspiriant LLC first reported a position in ALLO in Q3 2020 and held it in 1 quarter. The position peaked at $253K in Q3 2020. 165 funds tracked by Wall St. Rank hold ALLO as of Q4 2020.

  • Aspiriant LLC reported no remaining Allogene Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Aspiriant LLC sold 6,700 Allogene Therapeutics shares in Q4 2020, an estimated $253K.
  • Aspiriant LLC first reported a position in Allogene Therapeutics in Q3 2020 and held it in 1 quarter.
  • Aspiriant LLC's Allogene Therapeutics position peaked at $253K in Q3 2020.
  • 165 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2020.

Based on Aspiriant LLC's 13F filing for Q4 2020, filed 1 Feb 2021.